At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 17, 2026 at 08:02 ET
Tyra Biosciences appointed Habib J. Dable to its board of directors as a Class II director, effective April 16, 2026. Dable, a seasoned biopharma executive and current advisor at RA Capital, was granted stock options to purchase 44,400 shares. The move expands the board from nine to ten members.
- Habib J. Dable appointed to the board of directors effective April 16, 2026
- Board size increased from nine to ten members
- Dable is a former CEO of Acceleron Pharma and holds board roles at multiple biotech firms
- Granted options to purchase 44,400 shares of common stock, vesting over 36 months
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access